NuVasive (NASDAQ: NUVA) and Exactech (NASDAQ:EXAC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Institutional & Insider Ownership
58.9% of Exactech shares are owned by institutional investors. 1.2% of NuVasive shares are owned by insiders. Comparatively, 28.3% of Exactech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares NuVasive and Exactech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares NuVasive and Exactech’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NuVasive||$962.07 million||2.46||$37.14 million||$1.19||39.02|
NuVasive has higher revenue and earnings than Exactech. NuVasive is trading at a lower price-to-earnings ratio than Exactech, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for NuVasive and Exactech, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NuVasive currently has a consensus target price of $71.64, indicating a potential upside of 54.30%. Exactech has a consensus target price of $49.00, indicating a potential downside of 0.61%. Given NuVasive’s stronger consensus rating and higher probable upside, analysts clearly believe NuVasive is more favorable than Exactech.
Volatility and Risk
NuVasive has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Exactech has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
NuVasive beats Exactech on 9 of the 14 factors compared between the two stocks.
Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.
Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.